Behrens M, Comabella M, Lunemann J
Front Immunol. 2025; 15():1509927.
PMID: 39776919
PMC: 11703957.
DOI: 10.3389/fimmu.2024.1509927.
Pachner A, Pike S, Smith A, Gilli F
Biomolecules. 2025; 14(12.
PMID: 39766248
PMC: 11673926.
DOI: 10.3390/biom14121541.
Solares S, Leon J, Garcia-Gutierrez L
Cancers (Basel). 2025; 16(24.
PMID: 39766110
PMC: 11674381.
DOI: 10.3390/cancers16244212.
Vaccaro A, de Alves Pereira B, van de Walle T, Dimberg A
Methods Mol Biol. 2024; 2864:21-42.
PMID: 39527215
DOI: 10.1007/978-1-0716-4184-2_2.
Stys P, Tsutsui S, Gafson A, t Hart B, Belachew S, Geurts J
Front Cell Neurosci. 2024; 18:1426231.
PMID: 39161786
PMC: 11330826.
DOI: 10.3389/fncel.2024.1426231.
EBV and multiple sclerosis: expression of LMP2A in MS patients.
Agostini S, Mancuso R, Caputo D, Rovaris M, Clerici M
Front Neurosci. 2024; 18:1385233.
PMID: 38721048
PMC: 11076709.
DOI: 10.3389/fnins.2024.1385233.
Astrocyte Activation and Drug Target in Pathophysiology of Multiple Sclerosis.
Bisht P, Rathore C, Rathee A, Kabra A
Methods Mol Biol. 2024; 2761:431-455.
PMID: 38427254
DOI: 10.1007/978-1-0716-3662-6_30.
Progress in etiological diagnosis of viral meningitis.
Xu H, Chen P, Guo S, Shen X, Lu Y
Front Neurol. 2023; 14:1193834.
PMID: 37583954
PMC: 10423822.
DOI: 10.3389/fneur.2023.1193834.
Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection.
Hedstrom A
Front Immunol. 2023; 14:1212676.
PMID: 37554326
PMC: 10406387.
DOI: 10.3389/fimmu.2023.1212676.
Treatment Options for Epstein-Barr Virus-Related Disorders of the Central Nervous System.
Andersen O, Ernberg I, Hedstrom A
Infect Drug Resist. 2023; 16:4599-4620.
PMID: 37465179
PMC: 10351589.
DOI: 10.2147/IDR.S375624.
Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis.
Magliozzi R, Howell O, Calabrese M, Reynolds R
Nat Rev Neurol. 2023; 19(8):461-476.
PMID: 37400550
DOI: 10.1038/s41582-023-00838-7.
Markers of Epstein-Barr Virus Infection in Patients with Multiple Sclerosis.
Debuysschere C, Nekoua M, Hober D
Microorganisms. 2023; 11(5).
PMID: 37317236
PMC: 10220565.
DOI: 10.3390/microorganisms11051262.
Epstein-Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism.
Thomas O, Rickinson A, Palendira U
Clin Transl Immunology. 2023; 12(5):e1451.
PMID: 37206956
PMC: 10191779.
DOI: 10.1002/cti2.1451.
Potential biological contributers to the sex difference in multiple sclerosis progression.
Alvarez-Sanchez N, Dunn S
Front Immunol. 2023; 14:1175874.
PMID: 37122747
PMC: 10140530.
DOI: 10.3389/fimmu.2023.1175874.
From bedside to bench: how existing therapies inform the relationship between Epstein-Barr virus and multiple sclerosis.
Dyer Z, Tscharke D, Sutton I, Massey J
Clin Transl Immunology. 2023; 12(2):e1437.
PMID: 36844913
PMC: 9947628.
DOI: 10.1002/cti2.1437.
Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications.
Bjornevik K, Munz C, Cohen J, Ascherio A
Nat Rev Neurol. 2023; 19(3):160-171.
PMID: 36759741
DOI: 10.1038/s41582-023-00775-5.
A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis.
Kee R, Naughton M, McDonnell G, Howell O, Fitzgerald D
Biomedicines. 2022; 10(10).
PMID: 36289863
PMC: 9599335.
DOI: 10.3390/biomedicines10102604.
Altered Immune Response to the Epstein-Barr Virus as a Prerequisite for Multiple Sclerosis.
Laderach F, Munz C
Cells. 2022; 11(17).
PMID: 36078165
PMC: 9454695.
DOI: 10.3390/cells11172757.
Immunopathology of the optic nerve in multiple sclerosis.
Blanco L, Marzin M, Leistra A, van der Valk P, Nutma E, Amor S
Clin Exp Immunol. 2022; 209(2):236-246.
PMID: 35778909
PMC: 9390848.
DOI: 10.1093/cei/uxac063.
Association of Human Papillomavirus and Epstein-Barr Virus Infection with Tonsil Cancer in Northeastern Thailand.
Heawchaiyaphum C, Ekalaksananan T, Patarapadungkit N, Vatanasapt P, Pientong C
Asian Pac J Cancer Prev. 2022; 23(3):781-787.
PMID: 35345347
PMC: 9360956.
DOI: 10.31557/APJCP.2022.23.3.781.
